FDA approved medications targeting neurological conditions on September 5, 2025, while an aggressive tariff plan caused markets to tank.
6 reports, 1 independent
Updated Sep 5
Gone quiet
- Reports
- 6
- Developments
- 3
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved medications targeting neurological conditions on September 5, 2025, while an aggressive tariff plan caused markets to tank.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- FDA approved a nerve repair device on August 10, 2025, in partnership, with potential benefits linked to Trump-era tariffs and mentioned in stock analysis.Sub-event
- FDA approved prefilled syringe of Cortrophin Gel, noting strong uptake and concurrent discussion of Trump-era tariffs.Sub-event
FDA approved drugs for neurological conditions; aggressive tariff plan caused markets to tank.1 source
Keep exploring
The entities involved
-
Supernus Pharmaceuticals (United States)
company in Rockville, United States
Nothing else this week.
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- The US is pushing to tie drug prices to foreign rates, amid global trends of price controls and health technology assessments.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
- Trump, Dimon, and others discussed the threat of massive levies on imported pharmaceuticals while considering financial market trends in Ireland.
- The FDA operates under US law to evaluate international clinical data.
Coverage
Newest first; wire copies grouped- StockStory1 Cash-Producing Stock to Research Further and 2 We Brush Off A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ab
- StockStory2 Safe-and-Steady Stocks to Target This Week and 1 We Brush Off Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform d
- StockStory1 Momentum Stock for Long-Term Investors and 2 Facing Challenges The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product l
- StockStorySupernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 re
- StockStoryBranded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks,
- StockStory1 Stock Under $50 with Exciting Potential and 2 to Turn Down The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually